PharmaTelevision - Pfizer Inc's Polly Murphy on how creating a sustainable enterprise will allow them to make the biggest difference for patients,

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Pfizer Inc's Polly Murphy on how creating a sustainable enterprise will allow them to make the biggest difference for patients,

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Polly Murphy, Vice President R&D Business Development or Pfizer Inc,

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Changes in Pfizer's R&D innovation

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston, in September 2011. On this show I have Polly A. Murphy, who is Vice President of Worldwide R&D and Business Development at Pfizer , welcome to the show.

Polly A. Murphy:

Thank you.

Fintan Walton:

So Polly, obviously Pfizer is one of the largest pharmaceutical companies in the world like a lot of other companies that are large at the moment in pharmaceutical sector it's going changes and one of the noticeable changes that's taking place is the reduction in the amount of research and development going on closure as it sound which for an example moving research scientists around, even jobs been lost or gotten, so tell us what's actually going on with Pfizer? What's this change all about?

Polly A. Murphy:

So Pfizer believes that the right thing to do is to create a sustainable enterprise, it doesn't do anybody any good to not have a sustainable enterprise and that's where we end up in these constant cut cycles, so what Pfizer believe is trying to do is to really create the right sized R&D relative to the rest of the company so that we can be sustainable long into the future and the way we are doing that is by focusing and you know the ability to focus is actually a gift, because it allows you to do the things that can make the biggest difference for patients, so we've focused down on the disease areas that we believe we can have the most impact in creating innovating medicines that are differentiated and are great benefit to the people who need them.

Fintan Walton:

So these changes mean that obviously that there is a greater dependence on external research outside Pfizer?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Polly A Murphy

Vice President

Polly A. Murphy presently serves as Vice President, R&D Business Development of Pfizer Inc. Polly A. Murphy leads the Worldwide Business Development team that supports Pfizer 's R&D organization. This team is a global group of professionals focused on licensing and alliance management. She also serves on the Board of Directors for The Pfizer Incubator. Prior to Pfizer, she was Sr. Vice President, Business and Scientific Services at The Scripps Research Institute. In this role she led organization-wide business development and technology commercialization functions and was responsible for operation of the scientific support functions at the La Jolla campus. Before joining Scripps, Polly was VP, Office of Technology Management at the Salk Institute where she was responsible for protecting and commercializing Salk technologies. Previously she was in Business Development at Aurora Biosciences after holding several positions for Dupont Pharmaceuticals the last being vice president for portfolio planning and valuation. Of note, she headed the U.S. marketing team that launched DuPont Pharma's HIV drug Sustiva. Prior to Dupont, she worked for Nabi Biopharmaceuticals where she was director of business development. She began her career at Hoffman-LaRoche as a post-doc in the experimental pathology group followed by positions in sales and marketing. Polly holds Doctor of Veterinary Medicine and Ph.D. in Veterinary Pathology degrees from Iowa State University and an M.B.A. from Nova Southeastern University.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Pfizer Inc

Pfizer Inc incorporated on June 2, 1942, is a research-based, global biopharmaceutical company. The Company operates in two segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Diversified includes Animal Health products; Consumer Healthcare products, such as pain management therapies, cough/ cold / allergy remedies, dietary supplements, hemorrhoidal care and other personal care items; Nutrition products such as infant and toddler formula products, and Capsugel. On January 31, 2011, it acquired approximately 92.5% of King's common stock. In August 2011, the Company sold its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P.